Contemporary management of uterine fibroids: focus on emerging medical treatments

References

• Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician 2007;75:1503-8
   PubMed Web of Science ®Google Scholar
• Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435-8
   PubMed Web of Science ®Google Scholar
• Fields KR, Neinstein LS. Uterine myomas in adolescents: case reports and a review of the literature. J Pediatr Adolesc Gynecol 1996;9:195-8
   PubMedGoogle Scholar
• Downes E, Sikirica V, Gilabert-Estelles J, et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol 2010;152:96-102
   PubMed Web of Science ®Google Scholar
• Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-7
   PubMed Web of Science ®Google Scholar
• Weuve J, Hauser R, Calafat AM, et al. Association of exposure to phthalates with endometriosis and uterine leiomyomata: findings from NHANES, 1999–2004. Environ Health Perspect 2010;118:825-32
   PubMed Web of Science ®Google Scholar
• Zimmermann A, Bernuit D, Gerlinger C, et al. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Women's Health 2012;12:6
   PubMed Web of Science ®Google Scholar
• Canadian Institute for Health Information. Age-Standardized Hysterectomy Rates by Indication and Urban/Rural Dwelling, Canada, 2008–2009. 2013. Available at: https://secure.cihi.ca/free_products/Healthindicators2010_en.pdf [Last accessed 11 November 2013]
   Google Scholar
• Millar WJ. Hysterectomy, 1981/82 to 1996/97. Health Rep 2001;12:9-22
   PubMedGoogle Scholar
• Kunde K, Cortes E, Seed P, Khalaf Y. Evaluation of perioperative morbidity associated with single and multiple myomectomy. J Obstet Gynaecol 2009;29:737-41
   PubMedGoogle Scholar
• Makinen J, Johansson J, Tomas C, et al. Morbidity of 10110 hysterectomies by type of approach. Hum Reprod 2001;16:1473-8
   PubMed Web of Science ®Google Scholar
• Watson Laboratories Inc. FIBRISTAL (Ulipristal acetate) Product Monograph. Salt Lake City, UT. June 2013
   Google Scholar
• Hashimoto K, Azuma C, Kamiura S, et al. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Investig 1995;40:204-8
   PubMed Web of Science ®Google Scholar
• Islam MS, Protic O, Giannubilo SR, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metabol 2013;98:921-34
   PubMed Web of Science ®Google Scholar
• Rein MS, Friedman AJ, Barbieri RL, et al. Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol 1991;77:923-6
   PubMed Web of Science ®Google Scholar
• Kiechle-Schwarz M, Sreekantaiah C, Berger CS, et al. Nonrandom cytogenetic changes in leiomyomas of the female genitourinary tract. A report of 35 cases. Canc Genet Cytogenet 1991;53:125-36
   PubMed Web of Science ®Google Scholar
• Ligon AH, Morton CC. Genetics of uterine leiomyomata. Gene Chromosome Canc 2000;28:235-45
   PubMed Web of Science ®Google Scholar
• Mashal RD, Fejzo ML, Friedman AJ, et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Gene Chromosome Canc 1994;11:1-6
   PubMed Web of Science ®Google Scholar
• Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 2000;108(Suppl 5):791-3
   PubMed Web of Science ®Google Scholar
• Andersen J. Growth factors and cytokines in uterine leiomyomas. Semin Reprod Endocrinol 1996;14:269-82
   PubMedGoogle Scholar
• Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med 2010;28:180-203
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ishi K, Serna VA, et al. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 2010;151:2433-42
   PubMed Web of Science ®Google Scholar
• Englund K, Blanck A, Gustavsson I, et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metabol 1998;83:4092-6
   PubMed Web of Science ®Google Scholar
• Brandon DD, Erickson TE, Keenan EJ, et al. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metabol 1995;80:1876-81
   PubMed Web of Science ®Google Scholar
• Brandon DD, Bethea CL, Strawn EY, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993;169:78-85
   PubMed Web of Science ®Google Scholar
• Ichimura T, Kawamura N, Ito F, et al. Correlation between the growth of uterine leiomyomata and estrogen and progesterone receptor content in needle biopsy specimens. Fertil Steril 1998;70:967-71
   PubMed Web of Science ®Google Scholar
• Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000;65:585-92
   PubMed Web of Science ®Google Scholar
• Conneely OM, Mulac-Jericevic B, Lydon JP. Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 2003;68:771-8
   PubMed Web of Science ®Google Scholar
• Lora V, Grings AO, Capp E, et al. Gene and protein expression of progesterone receptor isoforms A and B, p53 and p21 in myometrium and uterine leiomyoma. Arch Gynecol Obstet 2012;286:119-24
   PubMed Web of Science ®Google Scholar
• Bulun SE. Uterine fibroids. N Engl J Med 2013;369:1344-55
   PubMed Web of Science ®Google Scholar
• Munro MG, Critchley HO, Broder MS, Fraser IS; Figo Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011;113:3-13
   PubMed Web of Science ®Google Scholar
• Wise LA, Palmer JR, Stewart EA, Rosenberg L. Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study. Obstet Gynecol 2005;105:563-8
   PubMed Web of Science ®Google Scholar
• Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967-73
   PubMed Web of Science ®Google Scholar
• Pron G, Cohen M, Soucie J, et al. The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril 2003;79:112-19
   PubMed Web of Science ®Google Scholar
• Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J 1986;293:359-62
   PubMed Web of Science ®Google Scholar
• Vikhlyaeva EM, Khodzhaeva ZS, Fantschenko ND. Familial predisposition to uterine leiomyomas. Int J Gynaecol Obstet 1995;51:127-31
   PubMed Web of Science ®Google Scholar
• Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432-9
   PubMed Web of Science ®Google Scholar
• Luoto R, Kaprio J, Rutanen EM, et al. Heritability and risk factors of uterine fibroids – the Finnish Twin Cohort study. Maturitas 2000;37:15-26
   PubMed Web of Science ®Google Scholar
• Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case–control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol 2001;153:11-19
   PubMed Web of Science ®Google Scholar
• Van Voorhis B. A 41-year-old woman with menorrhagia, anemia, and fibroids: review of treatment of uterine fibroids. JAMA 2009;301:82-93
   PubMed Web of Science ®Google Scholar
• Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009;91:1215-23
   PubMed Web of Science ®Google Scholar
• Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002;17:1424-30
   PubMed Web of Science ®Google Scholar
• Farquhar C. Do uterine fibroids cause infertility and should they be removed to increase fertility? BMJ 2009;338:b126
   PubMed Web of Science ®Google Scholar
• Rowe MK, Kanouse DE, Mittman BS, Bernstein SJ. Quality of life among women undergoing hysterectomies. Obstet Gynecol 1999;93:915-21
   PubMed Web of Science ®Google Scholar
• Bradley LD. Leiomyomas. In: Sokol AI, Sokol ER, eds. General Gynecology: The Requisites in Obstetrics and Gynecology. Mosby, 2007:459-80
   Google Scholar
• Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83:414-18
   PubMed Web of Science ®Google Scholar
• Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Canc 2006;119:2922-30
   PubMed Web of Science ®Google Scholar
• Rha SE, Byun JY, Jung SE, et al. CT and MRI of uterine sarcomas and their mimickers. Am J Roentgenol 2003;181:1369-74
   PubMed Web of Science ®Google Scholar
• Russell DJ. The female pelvic mass. Diagnosis and management. Med Clin 1995;79:1481-93
   Google Scholar
• AAGL Practice Report: Morcellation During Uterine Tissue Extraction. J Minim Invasive Gynecol 2014; 21(4):517-30
   Google Scholar
• Statistics Canada. Births. 2009. Available at: http://www.statcan.gc.ca/pub/84f0210x/2009000/aftertoc-aprestdm1-eng.htm [Last accessed 24 October 2013]
   Google Scholar
• Marret H, Fritel X, Ouldamer L, et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol 2012;165:156-64
   PubMed Web of Science ®Google Scholar
• Lefebvre G, Vilos G, Allaire C, et al. The management of uterine leiomyomas. J Obstet Gynaecol Canada 2003;25:396-418, quiz 19-22
   PubMedGoogle Scholar
• American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol 2008;112(2 Pt 1):387-400
   PubMedGoogle Scholar
• Cramer SF, Marchetti C, Freedman J, Padela A. Relationship of myoma cell size and menopausal status in small uterine leiomyomas. Arch Pathol Lab Med 2000;124:1448-53
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38
   PubMed Web of Science ®Google Scholar
• McKeage K, Croxtall JD. Ulipristal acetate: a review of its use in emergency contraception. Drugs 2011;71:935-45
   PubMed Web of Science ®Google Scholar
• Talaulikar VS, Manyonda IT. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids. Adv Ther 2012;29:655-63
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-20
   PubMed Web of Science ®Google Scholar
• Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014,101:1565-73
   Google Scholar
• Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009;21:318-24
   PubMed Web of Science ®Google Scholar
• Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metabol 1993;76:513-17
   PubMed Web of Science ®Google Scholar
• Carbonell Esteve JL, Acosta R, Heredia B, et al. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008;112:1029-36
   PubMed Web of Science ®Google Scholar
• Fiscella J, Bonfiglio T, Winters P, et al. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol 2011;42:947-53
   PubMed Web of Science ®Google Scholar
• AbbVie Inc. Lupron Depot 3.75 mg (leuprolide acetate for depot suspension) Prescribing information. North Chicago, IL. October 2013
   Google Scholar
• Friedman AJ, Rein MS, Harrison-Atlas D, et al. A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril 1989;52:728-33
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Zerhouni EA, Huth JA, et al. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol 1989;74:856-62
   PubMed Web of Science ®Google Scholar
• Golan A. GnRH analogues in the treatment of uterine fibroids. Hum Reprod 1996;11(Suppl 3):33-41
   PubMed Web of Science ®Google Scholar
• Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol 1995;86:65-71
   PubMed Web of Science ®Google Scholar
• Leyland N, Casper R, Laberge P, Singh SS; The Society of Obstetricians and Gynaecologists of Canada. Endometriosis: diagnosis and management. J Obstet Gynaecol Canada 2010;32(7 Suppl 2):S1-32
   PubMedGoogle Scholar
• Friedman AJ, Hoffman DI, Comite F, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol 1991;77:720-5
   PubMed Web of Science ®Google Scholar
• Chiaffarino F, Parazzini F, La Vecchia C, et al. Use of oral contraceptives and uterine fibroids: results from a case–control study. Br J Obstet Gynaecol 1999;106:857-60
   PubMedGoogle Scholar
• Mercorio F, De Simone R, Di Spiezio Sardo A, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception 2003;67:277-80
   PubMed Web of Science ®Google Scholar
• Bayer. Mirena (Levonorgestrel-releasing Intrauterine System) Product Monograph. Pointe-Claire, QC. June 2006
   Google Scholar
• Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;(4):CD000249
   Google Scholar
• Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994;73:274-7
   PubMed Web of Science ®Google Scholar
• Lakhani KP, Marsh MS, Purcell W, Hardiman P. Uterine artery blood flow parameters in women with dysfunctional uterine bleeding and uterine fibroids: the effects of tranexamic acid. Ultrasound Obstet Gynecol 1998;11:283-5
   PubMed Web of Science ®Google Scholar
• Ip PP, Lam KW, Cheung CL, et al. Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. Am J Surg Pathol 2007;31:1215-24
   PubMed Web of Science ®Google Scholar
• Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007;(4):CD000400
   PubMed Web of Science ®Google Scholar
• Singh S, Best C, Dunn S, et al.; The Society of Obstetricians and Gynaecologists of Canada. Abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol Canada 2013;35:473-9
   PubMedGoogle Scholar
• Shozu M, Murakami K, Segawa T, et al. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril 2003;79:628-31
   PubMed Web of Science ®Google Scholar
• Hilario SG, Bozzini N, Borsari R, Baracat EC. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril 2009;91:240-3
   PubMed Web of Science ®Google Scholar
• Gurates B, Parmaksiz C, Kilic G, et al. Treatment of symptomatic uterine leiomyoma with letrozole. Reprod Biomed Online 2008;17:569-74
   PubMed Web of Science ®Google Scholar
• Flierman PA, Oberye JJ, van der Hulst VP, de Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG: an International Journal of Obstetrics and Gynaecology 2005;112:638-42
   PubMed Web of Science ®Google Scholar
• Felberbaum RE, Germer U, Ludwig M, et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist cetrorelix. Hum Reprod 1998;13:1660-8
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barcena D, Alvarez RB, Ochoa EP, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist cetrorelix. Hum Reprod 1997;12:2028-35
   PubMed Web of Science ®Google Scholar
• Deng L, Wu T, Chen XY, et al. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 2012;10:CD005287
   PubMedGoogle Scholar
• Campo S, Garcea N. Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Hum Reprod 1999;14:44-8
   PubMed Web of Science ®Google Scholar
• Dubuisson JB, Fauconnier A, Fourchotte V, et al. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Hum Reprod 2001;16:1726-31
   PubMed Web of Science ®Google Scholar
• Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. Uterine fibroid embolization (UFE). Int J Gynaecol Obstet 2005;89:305-18
   PubMed Web of Science ®Google Scholar
• Pron G, Bennett J, Common A, et al. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril 2003;79:120-7
   PubMed Web of Science ®Google Scholar
• Gupta JK, Sinha AS, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev 2006;(1):CD005073
   PubMed Web of Science ®Google Scholar
• Broder MS, Goodwin S, Chen G, et al. Comparison of long-term outcomes of myomectomy and uterine artery embolization. Obstet Gynecol 2002;100(5 Pt 1):864-8
   PubMed Web of Science ®Google Scholar
• Spies JB, Bruno J, Czeyda-Pommersheim F, et al. Long-term outcome of uterine artery embolization of leiomyomata. Obstet Gynecol 2005;106(5 Pt 1):933-9
   PubMed Web of Science ®Google Scholar
• Mara M, Fucikova Z, Maskova J, et al. Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2006;126:226-33
   PubMed Web of Science ®Google Scholar
• Dutton S, Hirst A, McPherson K, et al. A UK multicentre retrospective cohort study comparing hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids (HOPEFUL study): main results on medium-term safety and efficacy. BJOG: an International Journal of Obstetrics and Gynaecology 2007;114:1340-51
   PubMed Web of Science ®Google Scholar
• Pron G, Mocarski E, Bennett J, et al. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol 2005;105:67-76
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Women’s and Children’s Health. Heavy Menstrual Bleeding. Clinical Guideline. 2007. Available at: http://www.nice.org.uk/nicemedia/pdf/CG44FullGuideline.pdf [Last accessed October 2014]
   Google Scholar
• Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;(2):CD000329
   PubMedGoogle Scholar
• Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopic electromyolysis. J Am Assoc Gynecologic Laparoscopists 1998;5:289-92
   PubMedGoogle Scholar
• Hindley J, Gedroyc WM, Regan L, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. Am J Roentgenol 2004;183:1713-19
   PubMed Web of Science ®Google Scholar
• Stewart EA, Rabinovici J, Tempany CM, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006;85:22-9
   PubMed Web of Science ®Google Scholar
• Alessandri F, Lijoi D, Mistrangelo E, et al. Randomized study of laparoscopic versus minilaparotomic myomectomy for uterine myomas. J Minim Invasive Gynecol 2006;13:92-7
   PubMed Web of Science ®Google Scholar
• Nezhat FR, Roemisch M, Nezhat CH, et al. Recurrence rate after laparoscopic myomectomy. J Am Assoc Gynecologic Laparoscopists 1998;5:237-40
   PubMedGoogle Scholar
• Garcia CR. Management of the symptomatic fibroid in women older than 40 years of age. Hysterectomy or myomectomy? Obstet Gynecol Clin N Am 1993;20:337-48
   PubMed Web of Science ®Google Scholar
• LaMorte AI, Lalwani S, Diamond MP. Morbidity associated with abdominal myomectomy. Obstet Gynecol 1993;82:897-900
   PubMed Web of Science ®Google Scholar
• Kjerulff KH, Rhodes JC, Langenberg PW, Harvey LA. Patient satisfaction with results of hysterectomy. Am J Obstet Gynecol 2000;183:1440-7
   PubMed Web of Science ®Google Scholar
• Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women's Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 1994;83:556-65
   PubMed Web of Science ®Google Scholar